niacinamide has been researched along with Thyroid Carcinoma, Anaplastic in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Thyroid Carcinoma, Anaplastic: An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash." | 9.17 | Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. ( Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ, 2013) |
| " Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash." | 5.17 | Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. ( Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ, 2013) |
| "Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer (DTC)." | 2.84 | Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. ( Ito, KI; Ito, Y; Kabu, K; Onoda, N; Sugitani, I; Takahashi, S; Tsukada, K; Yamaguchi, I, 2017) |
| "Anaplastic thyroid cancer (ATC) comprises approximately 2% of all thyroid cancers, and its median survival rate remains poor." | 1.43 | Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC). ( Abdulghani, J; Cooper, T; Derr, J; Dicker, D; El-Deiry, WS; Finnberg, NK; Gallant, JN; Gokare, P; Goldenberg, D; Liao, J; Liu, J; Whitcomb, T, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, Y | 1 |
| Onoda, N | 1 |
| Ito, KI | 1 |
| Sugitani, I | 1 |
| Takahashi, S | 1 |
| Yamaguchi, I | 1 |
| Kabu, K | 1 |
| Tsukada, K | 1 |
| Wunderlich, A | 1 |
| Khoruzhyk, M | 1 |
| Roth, S | 1 |
| Ramaswamy, A | 1 |
| Greene, BH | 1 |
| Doll, D | 1 |
| Bartsch, DK | 1 |
| Hoffmann, S | 1 |
| Abdulghani, J | 1 |
| Gokare, P | 1 |
| Gallant, JN | 1 |
| Dicker, D | 1 |
| Whitcomb, T | 1 |
| Cooper, T | 1 |
| Liao, J | 1 |
| Derr, J | 1 |
| Liu, J | 1 |
| Goldenberg, D | 1 |
| Finnberg, NK | 1 |
| El-Deiry, WS | 1 |
| Savvides, P | 1 |
| Nagaiah, G | 1 |
| Lavertu, P | 1 |
| Fu, P | 1 |
| Wright, JJ | 1 |
| Chapman, R | 1 |
| Wasman, J | 1 |
| Dowlati, A | 1 |
| Remick, SC | 1 |
| Cohen, SM | 1 |
| Mukerji, R | 1 |
| Timmermann, BN | 1 |
| Samadi, AK | 1 |
| Cohen, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid[NCT00126568] | Phase 2 | 20 participants (Actual) | Interventional | 2005-06-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The safety and toxicity profile of BAY 43-9006 as measured by toxicity grades of adverse events. (NCT00126568)
Timeframe: 27 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Sorafenib Tosylate) | 20 |
(NCT00126568)
Timeframe: 27 months
| Intervention | months (Median) |
|---|---|
| BAY 43-9006 | 3.9 |
(NCT00126568)
Timeframe: 27 months
| Intervention | months (Median) |
|---|---|
| BAY 43-9006 | 1.9 |
Response evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. The patient's best response depends on the achievement of measurement and confirmation criteria of Complete Response (CR), Stable Disease (SD), Partial Response (PR) or Progressive Disease (PD). Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques (CT, MRI, x-ray) or as >10 mm with spiral CT scan. (NCT00126568)
Timeframe: at 6 months after treatment
| Intervention | participants (Number) | ||
|---|---|---|---|
| Partial Response | Stable Disease | Progressive Disease | |
| BAY 43-9006 | 2 | 5 | 11 |
2 trials available for niacinamide and Thyroid Carcinoma, Anaplastic
| Article | Year |
|---|---|
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Neuroendocrine; Diarrhea; Drug Resistance, Neopla | 2017 |
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Drug Eruptions; Drug Resistance, Multiple; Drug Resis | 2013 |
3 other studies available for niacinamide and Thyroid Carcinoma, Anaplastic
| Article | Year |
|---|---|
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mi | 2013 |
Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Li | 2016 |
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papill | 2012 |